Boaz Weinstein’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Boaz Weinstein’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-270,751	Closed	-$2.71M	–	1005
2022 Q3	$2.71M	Hold	270,751	–	–	0.03%	604
2022 Q2	$2.68M	Hold	270,751	–	–	0.03%	629
2022 Q1	$2.67M	Buy	270,751 +214,300	+380%	+$2.1M	0.04%	545
2021 Q4	$551K	Buy	56,451 +29,577	+110%	+$290K	0.01%	622
2021 Q3	$263K	Buy	+26,874	New	+$262K	0.01%	486

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Boaz Weinstein's EUCR Position: Q4 2022 in Review

Boaz Weinstein sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 270,751 shares — an estimated $2.71M sold.

Boaz Weinstein first reported a position in EUCR in Q3 2021 and held it in 5 quarters. The position peaked at $2.71M in Q3 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Boaz Weinstein reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Boaz Weinstein sold 270,751 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $2.71M.
Boaz Weinstein first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q3 2021 and held it in 5 quarters.
Boaz Weinstein's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $2.71M in Q3 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Saba Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.